TY - JOUR

T1 - Fluctuations in serum levels of adalimumab and infliximab in patients on stable treatment for psoriasis

AU - Poulsen, Anne Sofie Konstantin

AU - Thomsen, Simon Francis

AU - Vinkel, Caroline

AU - Ghazanfar, Misbah Noshela

AU - Wulf-Johansson, Helle

AU - Bonne, Rikke

AU - Larsen, Rune

PY - 2020

Y1 - 2020

N2 - Many patients with psoriasis fail to respond to biologic drugs either initially or lose response over time, the latter having predominantly been linked to low circulating drug levels. We examined how serum drug levels varied over three treatment cycles of stable maintenance therapy with either adalimumab or infliximab among a total of 28 patients with psoriasis (22 men, mean age 48.6 years, mean treatment time 6.2 years) and whether there was an association with various patient-specific factors. The range for all concentrations was 1.1 to 24.3 μg/mL for adalimumab and 0.0 to 180.6 μg/mL for infliximab. There was a consistent inverse association between body mass index (BMI) and trough and maximum serum concentrations of adalimumab (P <.05 for all comparisons) and a positive, less consistent, association between age and maximum serum concentration of infliximab (P <.05 for both comparisons). Patient-specific factors, such as BMI and age, can help predict fluctuations in serum concentrations of biologics used for psoriasis.

AB - Many patients with psoriasis fail to respond to biologic drugs either initially or lose response over time, the latter having predominantly been linked to low circulating drug levels. We examined how serum drug levels varied over three treatment cycles of stable maintenance therapy with either adalimumab or infliximab among a total of 28 patients with psoriasis (22 men, mean age 48.6 years, mean treatment time 6.2 years) and whether there was an association with various patient-specific factors. The range for all concentrations was 1.1 to 24.3 μg/mL for adalimumab and 0.0 to 180.6 μg/mL for infliximab. There was a consistent inverse association between body mass index (BMI) and trough and maximum serum concentrations of adalimumab (P <.05 for all comparisons) and a positive, less consistent, association between age and maximum serum concentration of infliximab (P <.05 for both comparisons). Patient-specific factors, such as BMI and age, can help predict fluctuations in serum concentrations of biologics used for psoriasis.

KW - adalimumab

KW - drug levels

KW - infliximab

KW - psoriasis

UR - http://www.scopus.com/inward/record.url?scp=85085594870&partnerID=8YFLogxK

U2 - 10.1111/dth.13497

DO - 10.1111/dth.13497

M3 - Journal article

C2 - 32359001

AN - SCOPUS:85085594870

VL - 33

JO - Dermatologic Therapy

JF - Dermatologic Therapy

SN - 1396-0296

IS - 4

M1 - e13497

ER -